MSH2 and duodenum cancer: While for those with a MLH1 or MSH2 pathogenic variant the lifetime risk of duodenal cancer is as high as 10–11%, the risk for carriers of other pathogenic variants is widely ranging, with suggestion that PMS2 carriers have a risk no higher than the general population [10,12].